Narusawa, Eriko http://orcid.org/0009-0009-3896-2823
Kurozumi, Sasagu
Katayama, Ayaka
Koibuchi, Yukio
Ogawa, Akira
Takata, Daisuke
Tokuda, Shoko
Obayashi, Sayaka
Oyama, Tetsunari
Horiguchi, Jun
Shirabe, Ken
Fujii, Takaaki
Article History
Received: 10 November 2023
Accepted: 8 March 2024
First Online: 15 April 2024
Declarations
:
: SK has received honoraria from Kyowa Kirin Co., Ltd.; Daiichi Sankyo Co. Ltd.; Taiho Pharmaceutical Co. Ltd.; Eli Lilly and Company, MSD K.K.; AstraZeneca K.K.; Chugai Pharmaceutical, Ltd.; Dinow Inc.; Eisai Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; and Novartis Japan. TF received research funding from Eisai Co., Ltd. KS received research grants from Chugai Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. The other authors declare that they have no conflicts of interest.
: This study was approved by National Hospital Organization Takasaki General Medical Center (reference no. 2020-46). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.